Navigation Links
Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Date:2/15/2008

SAN DIEGO, Feb. 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Cadence has received commitments from selected investors to purchase up to 9,240,307 shares of Cadence's common stock at a purchase price of $5.34 per share pursuant to an effective shelf registration statement.

The closing of the offering is expected to take place on February 20, 2008. The total number of shares to be sold in the offering may be reduced to 8,056,716 and the gross proceeds may be reduced to $43.0 million pursuant to Nasdaq Marketplace Rule 4350(i)(1)(B) limitations, pending the determination of the applicability of such rule prior to the closing of the offering.

Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Cadence Pharmaceuticals, Inc., 12481 High Bluff Drive, Suite 200, San Diego, California, Attention: General Counsel, or by calling (858) 436-1400.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetava
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 Sales Horizons, ... of its online sales training course – Mastering ... their sales performance. , Drawn from proven sales training ... companies, Mastering the Complex Sale online sales training course ... anyone who has face-to-face contact with customers, like technical ...
(Date:7/30/2014)... 2014  Decision Resources Group finds that the ... the United States believe ... will be the level of savings achievable by ... lower cost to patients. Payers plan to leverage ... pricing expectations in order to encourage physician prescribing ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 While ... in health services research for a relatively long ... in interest regarding the use of these ‘big ... conditions. , By combining today’s powerful computer technology ... digital era, ‘big data’ holds significant promise for ...
(Date:7/30/2014)... With the accelerated aging of ... expenditure as well as the improved medical care ... reagent industry has been developing quickly, especially in ... Chinese in vitro diagnostics market size reached RMB22.98 ... vitro diagnostic reagents. , Read complete report ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3
(Date:7/31/2014)... , July 31, 2014 ... unique and innovative smart technologies; companies turn towards digital ... EBAY ), Amazon.com Inc. (NASDAQ: AMZN ... Inc. (NASDAQ: GOOG ) and Microsoft Corporation ... company focused on the growing m-commerce market, announces a ...
(Date:7/30/2014)... New York University is paving the way for ... civilians and military troops exposed to poisonous chemicalsparticularly ... An article in the current issue of the ... detoxifying organophosphates, which are compounds commonly used in ... developed by NYU School of Engineering Associate Professor ...
(Date:7/30/2014)... American Chemical Society (ACS) announced today that David L. ... ACS Biomaterials Science & Engineering as editor-in-chief. With ... the new journal will feature high-quality research in the ... or naturally derived materials that interact with living or ... it reflects the tremendous growth in the field of ...
Breaking Biology News(10 mins):Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6Engineering a protein to prevent brain damage from toxic agents 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... disabilities who are struggling to regain the use of ... engineers and students from Rochester Institute of Technology. ... the human body, to improve the performance of external ... disabilities, such as strokes or major spinal cord injuries, ...
... know all there is to know about Escherichia coli, ... has more than four thousand genes, and the functions ... Siegele, a biology professor at Texas A&M University whose ... , Harmless E. coli strains are normally found in ...
... Understanding, through its Institute for Arctic Studies, has ... Science Foundation through its Integrative Graduate Education and ... grant supports the development of an interdisciplinary doctoral ... a focus on rapid environmental change. "This grant ...
Cached Biology News:Robotics research: Enhancing the lives of people with disabilities 2GIANT-Coli: A novel method to quicken discovery of gene function 2Dartmouth awarded NSF grant for new polar sciences, engineering grad program 2Dartmouth awarded NSF grant for new polar sciences, engineering grad program 3